Position for potential regulatory filings and approval acceleration; monitor upcoming medical meeting presentations for detailed efficacy and safety data. Consider incremental value of Ultomiris expansion into IgAN, a high-unmet-need market with limited current therapies.
AZN drugs
AZN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 21 $195.77entry
- T+1 · 7mo ago −0.50%α −1.51% · $194.80
- T+5 · 7mo ago −4.73%α −5.81% · $186.51
- T+20 · 6mo ago −6.05%α −10.97% · $183.92
- T+60 · 4mo ago −13.52%α −20.15% · $169.29
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca announced positive interim results from the Phase III I CAN trial, showing that Ultomiris (ravulizumab) met its primary endpoint with a statistically significant and clinically meaningful reduction in proteinuria in adults with immunoglobulin A nephropathy (IgAN). The company plans to seek accelerated approval in key markets and present full results at a future medical meeting.
Key Facts
- Ultomiris met the primary endpoint of statistically significant and clinically meaningful reduction in proteinuria (measured by 24-hour UPCR) at week 34 in the I CAN Phase III trial.
- The trial enrolled approximately 510 adults with IgAN at risk of disease progression across 28 countries.
- Ultomiris demonstrated rapid reduction in proteinuria as early as week 10.
- The safety profile was consistent with known data, with no new safety concerns.
- AstraZeneca plans to file for accelerated approval in key markets and present results at a forthcoming medical meeting.
Financial Impact
High potential revenue upside given the unmet need in IgAN and the drug's prior approval in other rare diseases; market opportunity supported by over 560,000 diagnosed patients in US, EU5, and Japan.
Risk Factors
- Final trial results at week 106 (eGFR change) may not confirm long-term benefit.
- Regulatory agencies may require additional data beyond the interim analysis for full approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003757 |
| Document: 0001654954-26-003757-index-headers.html | 0001654954-26-003757 |
| Document: 0001654954-26-003757-index.html | 0001654954-26-003757 |
| Document: 0001654954-26-003757.txt | 0001654954-26-003757 |
Track record
77 reports on AZN
19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers